Isolated populations of female germline stem cells and cell preparations and compositions thereof

Patent metadata

Field	Value
Publication number	US-9962411-B2
Application number	US-201414315220-A
Country	US
Kind code	B2
Filing date	Jun 25, 2014
Priority date	May 17, 2004
Publication date	May 8, 2018
Grant date	May 8, 2018

Abstract

The present invention relates to female germline stem cells and their progenitors, methods of isolation thereof, and methods of use thereof.

First claim

We claim:

1. A method of producing an oocyte in a female mammalian subject in need thereof, comprising:
obtaining non-embryonic stem cells from the ovarian tissue;
purifying the stem cells by isolating from the stem cells a population of cells that are mitotically competent and express Vasa, Oct-4, Dazl, and Stella and, optionally, a stage-specific embryonic antigen, thereby obtaining a purified population of female germline stem cells:
preparing a composition comprising a therapeutically effective amount of the purified population of female germline stem cells, wherein said purified population of female germline stem cells are autologous or allogenic, and a pharmaceutically acceptable carrier: and
administering said composition to an ovary of the subject, wherein the cells engraft into the ovary, thereby producing an oocyte in the subject.

2. A method of inducing folliculogenesis in a female subject in need thereof, comprising:
obtaining non-embryonic stem cells from ovarian tissue;
purifying the stem cells by isolating from the stem cells a population of cells that are mitotically competent and express Vasa, Oct-4, Dazl, and Stella and, optionally, a stage-specific embryonic antigen, thereby obtaining a purified population of female germline stem cells;
preparing a composition comprising a therapeutically effective amount of the purified population of female germline stem cells, wherein said purified population of female germline stem cells are autologous or allogenic, and a pharmaceutically acceptable carrier: and
administering said composition to an ovary of the subject, thereby inducing folliculogenesis in the subject.

3. A method of treating infertility in a female subject in need thereof comprising:
obtaining non-embryonic stem cells from ovarian tissue;
purifying the stem cells by isolating from the stem cells a population of cells that are mitotically competent and express Vasa, Oct-4, Dazl, and Stella and, optionally, a stage-specific embryonic antigen, thereby obtaining a purified population of female germline stem cells:
preparing a composition comprising a therapeutically effective amount of the purified population of female germline stem cells, wherein said purified population of female germline stem cells are autologous or allogenic, and a pharmaceutically acceptable carrier: and
administering said composition into an ovary of the subject, thereby treating infertility.

4. The method of any of claims 1 , 2 , and 3 , wherein the cells are human cells.

5. The method of claim 4 , wherein the purified population of cells is about 50 to about 55%, about 55 to about 60%, about 65 to about 70%, about 70 to about 75%, about 75 to about 80%, about 80 to about 85%, about 90 to about 95% or about 95 to about 100% of the cells in the population.

6. The method of any one of claims 1 , 2 and 3 , wherein the stage-specific embryonic antigen is stage-specific embryonic antigen-1.

7. The method of any one of claims 1 , 2 and 3 , wherein the human cells are cells from a human female having exhausted ovarian or follicular reserves.

8. The method of any one of claims 1 , 2 and 3 , wherein the step of isolating comprises isolating a first population of mitotically active cells from a sample of ovarian tissue by selecting cells in the sample that express a first genetic marker selected from a stage-specific embryonic antigen, Vasa, Oct-4, Dazl or Stella.

9. The method of claim 8 , wherein the isolating step further comprises isolating one or more mitotically active cells from said first population by selecting the expression of a second genetic marker by the mitotically active cells, wherein the second genetic marker is selected from a stage-specific embryonic antigen, Vasa, Oct-4, Dazl or Stella, and said second genetic marker is different from said first genetic marker.

10. The method of claim 3 , wherein an oocyte results from the engrafted cells, and wherein the method further comprises:
removing the oocyte from the female subject; fertilizing the oocyte in vitro to form a zygote; and
inserting the zygote or a multi-celled embryo derived from the zygote into the female subject.

11. The method of claim 8 , wherein the isolating step comprises selecting protein corresponding to the first genetic marker.

12. The method of claim 8 , wherein the first genetic marker is Vasa.

13. The method of claim 12 , wherein the selection of cells in the sample comprises contacting the sample with a multiplicity of antibodies comprising an antibody that specifically binds to human Vasa.

14. The method of claim 8 , wherein the isolating step comprises fluorescence activated cell sorting.

Assignees

• Massachusetts Gen Hospital

Inventors

• Tilly Jonathan Lee
• Johnson Joshua

Classifications

• A01K2217/05

  Animals comprising random inserted nucleic acids (transgenic) · CPC title

• C12N5/0607

  Non-embryonic pluripotent stem cells, e.g. MASC (induced pluripotent stem cells C12N5/0696) · CPC title

• A01K2267/0393

  Animal model comprising a reporter system for screening tests · CPC title

• A61K35/54 Primary

  Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells · CPC title

• A61P15/08

  for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis · CPC title